Whether increased serum MIF has predictive value that is independent of known predictive markers such as rising PSA values or Gleason score in prostate cancer awaits a larger trial that compares these variables prospectively with PSA levels and patient outcomes. The gene discussed is MIF; the disease is prostate carcinoma.